Losartan therapy for Raynaud's phenomenon and scleroderma: Clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial
Open Access
- 1 December 1999
- journal article
- clinical trial
- Published by Wiley in Arthritis & Rheumatism
- Vol. 42 (12), 2646-2655
- https://doi.org/10.1002/1529-0131(199912)42:12<2646::aid-anr21>3.0.co;2-t
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Angiotensin II antagonists: efficacy, duration of action, comparison with other drugsJournal of Human Hypertension, 1998
- Angiotensin receptor antagonists: focus on losartanThe Lancet, 1995
- Raynaud's phenomenonThe Lancet, 1995
- Angiotensin Converting Enzyme Inhibitors in Raynaud??s PhenomenonDrugs, 1994
- Effects of Low-Dose Nifedipine on a Cold Provocation Test in Patients with Raynaudʼs DiseaseJournal of Cardiovascular Pharmacology, 1990
- Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosisBritish Journal of Dermatology, 1987
- Acute Effects of Sublingual Nifedipine in Patients with Raynaudʼs PhenomenonJournal of Cardiovascular Pharmacology, 1987
- The Effect of the Calcium‐entry Blocker Nifedipine on Cold‐induced Digital VasospasmActa Medica Scandinavica, 1987
- Controlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud's phenomenonAmerican Heart Journal, 1986
- CONTROLLED TRIAL OF NIFEDIPINE IN THE TREATMENT OF RAYNAUD'S PHENOMENONThe Lancet, 1982